Literature DB >> 8736405

Deferring adjuvant therapy for totally resected intracranial ependymoma.

Y M Awaad1, J C Allen, D C Miller, S J Schneider, J Wisoff, F J Epstein.   

Abstract

Radical surgery is the most important treatment modality for ependymoma. The benefit of adjuvant radiotherapy and/or chemotherapy following a gross total resection of a low grade intracranial ependymoma is uncertain. Since 1990 we elected to defer adjuvant therapy in 7 pediatric patients with a median age of 7 years (range 3-16 years) who had a radical resection of an intracranial ependymoma and no evidence of central nervous system metastases. The primary tumor site was the cerebral hemisphere (6) and the cerebellum (1). A gross total resection was radiologically confirmed in 5 of the 7 patients. Two of the patients had a blood clot in the resection site on the postoperative magnetic resonance imaging scan. All patients are alive after a median follow-up of 44 months and the median progression-free survival is 38+ months. Five of the patients remain in continuous remission. The 2 patients with postoperative blood clots developed subclinical local recurrences, 10 and 11 months, respectively, after diagnosis. They remain in remission for 13+ and 27+ months after subsequent radical surgical procedures. Involved field radiotherapy was administered to 1 patient. After a limited period of follow-up, radical surgery alone appears to be sufficient for the majority of children with low grade ependymomas diagnosed at > 3 years of age when postoperative imaging confirms a gross total resection. This is more likely to occur in supratentorial ependymomas arising in older children.

Entities:  

Mesh:

Year:  1996        PMID: 8736405     DOI: 10.1016/0887-8994(96)00020-3

Source DB:  PubMed          Journal:  Pediatr Neurol        ISSN: 0887-8994            Impact factor:   3.372


  14 in total

Review 1.  Pediatric surgical neuro-oncology: current best care practices and strategies.

Authors:  James T Rutka; John S Kuo
Journal:  J Neurooncol       Date:  2004 Aug-Sep       Impact factor: 4.130

2.  Ependymoma: lessons from the past, prospects for the future.

Authors:  Eric Bouffet; Uri Tabori; Annie Huang; Ute Bartels
Journal:  Childs Nerv Syst       Date:  2009-06-27       Impact factor: 1.475

3.  Natural history and role of radiation in patients with supratentorial and infratentorial WHO grade II ependymomas: results from a population-based study.

Authors:  Ayal A Aizer; Marek Ancukiewicz; Paul L Nguyen; Shannon M Macdonald; Torunn I Yock; Nancy J Tarbell; Helen A Shih; Jay S Loeffler; Kevin S Oh
Journal:  J Neurooncol       Date:  2013-09-21       Impact factor: 4.130

4.  Multivariate analysis of clinical prognostic factors in children with intracranial ependymomas.

Authors:  Tang-Her Jaing; Huei-Shyong Wang; Pei-Kwei Tsay; Chen-Kan Tseng; Shih-Ming Jung; Kuang-Lin Lin; Tai-Ngar Lui
Journal:  J Neurooncol       Date:  2004-07       Impact factor: 4.130

5.  The history of ependymoma management.

Authors:  Kyu-Won Shim; Dong-Seok Kim; Joong-Uhn Choi
Journal:  Childs Nerv Syst       Date:  2009-05-21       Impact factor: 1.475

Review 6.  Multidisciplinary management of pediatric intracranial ependymoma.

Authors:  David B Mansur
Journal:  CNS Oncol       Date:  2013-05

Review 7.  Childhood ependymoma: a systematic review of treatment options and strategies.

Authors:  Jacques Grill; Chastagner Pascal; Kalifa Chantal
Journal:  Paediatr Drugs       Date:  2003       Impact factor: 3.022

Review 8.  Ependymomas.

Authors:  Marc C Chamberlain
Journal:  Curr Neurol Neurosci Rep       Date:  2003-05       Impact factor: 5.081

Review 9.  Ependymoma.

Authors:  Charles Teo; Peter Nakaji; Patricia Symons; Vivienne Tobias; Richard Cohn; Robert Smee
Journal:  Childs Nerv Syst       Date:  2003-05-22       Impact factor: 1.475

Review 10.  The management of completely resected childhood intracranial ependymoma: the argument for observation only.

Authors:  Andrew S Little; Tyson Sheean; Ragavan Manoharan; Aneela Darbar; Charles Teo
Journal:  Childs Nerv Syst       Date:  2009-01-20       Impact factor: 1.475

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.